Basal Cell Carcinoma (Basal Cell Epithelioma) Treatment Market Size Report 2034: Emerging Therapies and Future Growth Opportunities

DelveInsight's "Basal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of Basal Cell Carcinoma, historical and forecasted epidemiology as well as the Basal Cell Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover Key Insights into the Basal Cell Carcinoma Market with DelveInsight's In-Depth Report @ Basal Cell Carcinoma Market Size- https://www.delveinsight.com/sample-request/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Basal Cell Carcinoma Market
• In February 2025, BPGbio conducted a study to evaluate the safety and tolerability of the pharmaceutical compound API 31510 in a topical cream formulation. The cream will be applied to superficial basal cell carcinomas to assess its preliminary efficacy in treating these lesions. The study will involve 160 otherwise healthy male or female adults with one or more histologically confirmed superficial basal cell carcinoma lesions. A single target lesion, measuring less than one inch in area, will be designated for treatment.
• The incidence of BCC is higher in individuals aged 40 to 70 years due to the reduced ability to repair the UVR-induced DNA damage with advancing age.
• Women under 40 have a higher incidence of BCC, while in older age, the disease is predominantly observed in men.
• In approximately 80% of the cases BCC is located on the face and neck.
• Approximately 60% of both familial and sporadic cases of BCCs exhibit genetic alterations within the microsatellite D6S251 located in the 6q14 region.
• The leading Basal Cell Carcinoma Companies such as F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., Allergan, AstraZeneca, Johnson & Johnson Private Limited, Cipla Inc., Abbott, AbbVie Inc., Merck KGaA, LEO Pharma A/S, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin, Hikma Pharmaceuticals PLC, Fresenius Kabi AG, Amneal Pharmaceuticals LLC, MediWound Ltd, AiViva BioPharma, Inc., SkinJect, Inc., Berg, LLC, Anne Chang, University of Arizona, and others.
• Promising Basal Cell Carcinoma Therapies such as EscharEx 5% (EX-02 formulation), AIV001, API 31510 3% Topical Cream, Vismodegib, STP705, and others.

Request a sample for the Basal Cell Carcinoma Market Report @ Basal Cell Carcinoma Market Forecast- https://www.delveinsight.com/sample-request/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Basal Cell Carcinoma Epidemiology Segmentation in the 7MM
• Total Prevalence of Basal Cell Carcinoma
• Prevalent Cases of Basal Cell Carcinoma by severity
• Gender-specific Prevalence of Basal Cell Carcinoma
• Diagnosed Cases of Episodic and Chronic Basal Cell Carcinoma

Download the report to understand which factors are driving Basal Cell Carcinoma Epidemiology trends @ Basal Cell Carcinoma Prevalence- https://www.delveinsight.com/sample-request/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Basal Cell Carcinoma Marketed Drugs

• LIBTAYO: Regeneron Pharmaceuticals
LIBTAYO (cemiplimab-rwlc) is a programmed death receptor-1 (PD-1) blocking antibody indicated for Cutaneous Squamous Cell Carcinoma (CSCC), Basal Cell Carcinoma and Non-Small Cell Lung Cancer (NSCLC). Cemiplimab-rwlc, a recombinant human IgG4 monoclonal antibody, disrupts the interaction between PD-1 receptor on T cells and its ligands, PD-L1 and PD-L2. By doing so, it prevents the inhibition of T-cell proliferation and cytokine production. This release of PD-1 pathway-mediated inhibition boosts the anti-tumor immune response, leading to decreased tumor growth.

• ERIVEDGE: Genentech
ERIVEDGE (vismodegib) is a hedgehog pathway inhibitor indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who not candidates for radiation are. The recommended dosage is 150 mg orally once daily. Vismodegib is an inhibitor of the Hedgehog pathway. Vismodegib binds to and inhibits Smoothened, a transmembrane protein involved in Hedgehog signal transduction.

Emerging Basal Cell Carcinoma Drugs

• Patidegib (SGT-610) : Sol-Gel Technologies
Patidegib is an investigational small molecule that inhibits hedgehog signaling. It is a topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib is currently evaluated in Phase III clinical trials for the treatment of BCCs.

• AIV001: AiViva BioPharma
AIV001 is a novel formulation of a multi-kinase inhibitor combined with AiViva's proprietary delivery technology, designed for prolonged drug release via intradermal treatment. AIV001 targets multiple pathways to reduce fibroplasia in overlapping phases of wound healing and scarring; targets VEGFR to limit the inflammation and fibrosis associated with rosacea; and inhibits or reduces neovascularization and cell proliferation associated with certain cancers. AIV001 is in Phase I/II clinical studies for the treatment of patients with Basal Cell Carcinoma.

To learn more about Basal Cell Carcinoma treatment guidelines, visit @ Basal Cell Carcinoma Treatment Market Landscape- https://www.delveinsight.com/sample-request/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Basal Cell Carcinoma Therapies and Companies
• EscharEx 5% (EX-02 formulation): MediWound Ltd
• AIV001: AiViva BioPharma, Inc.
• API 31510 3% Topical Cream: SkinJect, Inc.
• Vismodegib: Berg, LLC
• STP705: Anne Chang

Basal Cell Carcinoma Market Drivers
• Rise in number of cases of basal cell carcinoma
• Increase in R&D

Basal Cell Carcinoma Market Barriers
• Resistance against systemic treatment Options
• High Cost of Basal Cell Carcinoma treatment

Request for Sample Report @ Basal Cell Carcinoma Therapies and Drugs- https://www.delveinsight.com/sample-request/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Basal Cell Carcinoma Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Basal Cell Carcinoma Companies: F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., Allergan, AstraZeneca, Johnson & Johnson Private Limited, Cipla Inc., Abbott, AbbVie Inc., Merck KGaA, LEO Pharma A/S, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin, Hikma Pharmaceuticals PLC, Fresenius Kabi AG, Amneal Pharmaceuticals LLC, MediWound Ltd, AiViva BioPharma, Inc., SkinJect, Inc., Berg, LLC, Anne Chang, University of Arizona, and others.
• Basal Cell Carcinoma Therapies: EscharEx 5% (EX-02 formulation), AIV001, API 31510 3% Topical Cream, Vismodegib, STP705, and others
• Therapeutic Assessment: Basal Cell Carcinoma current marketed and Basal Cell Carcinoma emerging therapies
• Basal Cell Carcinoma Market Dynamics: Basal Cell Carcinoma market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Basal Cell Carcinoma Market Access and Reimbursement

Discover more about Basal Cell Carcinoma Drugs in development @ Basal Cell Carcinoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/basal-cell-carcinoma-basal-cell-epithelioma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Basal Cell Carcinoma Market Report Introduction
2. Executive Summary for Basal Cell Carcinoma
3. SWOT analysis of Basal Cell Carcinoma
4. Basal Cell Carcinoma Patient Share (%) Overview at a Glance
5. Basal Cell Carcinoma Market Overview at a Glance
6. Basal Cell Carcinoma Disease Background and Overview
7. Basal Cell Carcinoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Basal Cell Carcinoma
9. Basal Cell Carcinoma Current Treatment and Medical Practices
10. Basal Cell Carcinoma Unmet Needs
11. Basal Cell Carcinoma Emerging Therapies
12. Basal Cell Carcinoma Market Outlook
13. Country-Wise Basal Cell Carcinoma Market Analysis (2019-2032)
14. Basal Cell Carcinoma Market Access and Reimbursement of Therapies
15. Basal Cell Carcinoma Market drivers
16. Basal Cell Carcinoma Market barriers
17. Basal Cell Carcinoma Appendix
18. Basal Cell Carcinoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.